INTRA-CELLULAR THERAPIES INC (ITCI)
US46116X1019 - Common Stock
ChartMill assigns a Buy % Consensus number of 83% to ITCI. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 85.45. This target is 16.68% above the current price.
ITCI was analyzed by 22 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about ITCI.
In the previous month the buy percentage consensus was at a similar level.
ITCI was analyzed by 22 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-04-17 | TD Cowen | Maintains | Buy -> Buy |
| 2024-04-17 | Baird | Maintains | Outperform -> Outperform |
| 2024-04-17 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-04-17 | B of A Securities | Maintains | Buy -> Buy |
| 2024-04-16 | Needham | Reiterate | Buy -> Buy |
| 2024-04-05 | Needham | Reiterate | Buy -> Buy |
| 2024-04-03 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-02-23 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-02-23 | Needham | Maintains | Buy -> Buy |
| 2024-02-23 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-02-23 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-02-16 | Mizuho | Maintains | Buy -> Buy |
| 2024-01-31 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-01-18 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-01-03 | Baird | Initiate | Outperform |
| 2024-01-02 | B of A Securities | Maintains | Buy -> Buy |
| 2023-12-14 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-12-11 | TD Cowen | Initiate | Outperform |
| 2023-11-03 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2023-11-03 | Needham | Maintains | Buy -> Buy |
| 2023-11-03 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-08-22 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-08-04 | Needham | Maintains | Buy -> Buy |
| 2023-08-04 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-08-04 | Morgan Stanley | Reiterate | Overweight -> Overweight |
| 2023-08-03 | Needham | Reiterate | Buy |
| 2023-07-11 | Morgan Stanley | Reiterate | Overweight -> Overweight |
| 2023-07-06 | Needham | Maintains | Buy -> Buy |
| 2023-06-23 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-06-22 | RBC Capital | Reiterate | Outperform -> Outperform |